Ginsenoside Rh2 attenuates allergic airway inflammation by modulating nuclear factor-κB activation in a murine model of asthma

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6946-6954

  Li, Liang Chang ^a   Piao, Hong Mei ^a   Zheng, Ming Yu ^a   Lin, Zhen Hua ^a   Choi, Yun Ho ^b   Yan, Guang Hai ^a  

^a YANBIAN UNIVERSITY   (China)

^b Chonbuk National University   (South Korea)

Author keywords

Airway inflammation; Asthma; Ginsenoside Rh2; Nuclear factor kappa B; T helper cell type 2 cytokines

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; GINSENOSIDE RH 2; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; GINSENOSIDE; OVALBUMIN;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EOSINOPHIL; FEMALE; HISTOLOGY; INFLAMMATORY CELL; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE; MOUSE; MURINE MODEL; NEUTROPHIL; NONHUMAN; PROTEIN DETERMINATION; WESTERN BLOTTING; ANIMAL; ASTHMA; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LUNG; PATHOLOGY;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; FEMALE; GINSENOSIDES; IMMUNOGLOBULIN E; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; LUNG; MICE; MICE, INBRED BALB C; NF-KAPPA B; OVALBUMIN;

EID: 84943628947     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4272     Document Type: Article

References (42)

1. Kay AB: Asthma and infl ammation. J Allergy Clin Immunol 87: 893-910, 1991.
2. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP and Wauben MH: Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: Amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 164: 580-588, 2000.
3. Mazzarella G, Bianco A, Catena E, De Palma R and Abbate GF: Th1/Th2 lymphocyte polarization in asthma. Allergy 55 (Suppl 61): S6-S9, 2000.
4. Primhak RA and Powell CV: AHR in asthma. Thorax 57: 186, 2002.
5. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR and Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326: 298-304, 1992.
6. Tournoy KG, Kips JC and Pauwels RA: Is Th1 the solution for Th2 in asthma? Clin Exp Allergy 32: 17-29, 2002.
7. Umetsu DT, McIntire JJ, Akbari O, Macaubas C and DeKruyff RH: Asthma: An epidemic of dysregulated immunity. Nat Immunol 3: 715-720, 2002.
8. Bao Z, Guan S, Cheng C, Wu S, Wong SH, Kemeny DM, Leung BP and Wong WS: A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. Am J Respir Crit Care Med 179: 657-665, 2009.
9. Janssen-Heininger YM, Poynter ME, Aesif SW, Pantano C, Ather JL, Reynaert NL, Ckless K, Anathy V, van der Velden J, Irvin CG and van der Vliet A: Nuclear factor kappaB airway epithelium and asthma: Avenues for redox control. Proc Am Thorac Soc 6: 249-255, 2009.
10. Xu S, Xu Y, Zhang Z, Ni W and Chen S: Effect of nuclear factor-kappaB on airway remodeling in asthmatic rats. J Huazhong Univ Sci Technolog Med Sci 24: 13-18, 2004.
11. Schieven GL: The biology of p38 kinase: A central role in infl ammation. Curr Top Med Chem 5: 921-928, 2005.
12. Fu J, Meng X, He J and Gu J: Inhibition of infl ammation by a p38 MAP kinase targeted cell permeable peptide. Med Chem 4: 597-604, 2008.
13. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW and Natarajan V: Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells Biochem J 393: 657-668, 2006.
14. Saccani S, Pantano S and Natoli G: p38-Dependent marking of infl ammatory genes for increased NF-kappa B recruitment. Nat Immunol 3: 69-75, 2002.
15. Woo CH, Lim JH and Kim JH: Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 2647 cells. J Immunol 173: 6973-6980, 2004.
16. Park HM, Kim SJ, Kim JS and Kang HS: Reactive oxygen species mediated ginsenoside Rg3-and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol 50: 2736-2741, 2012.
17. Chan SW: Panax ginseng Rhodiola rosea and Schisandra chinensis. Int J Food Sci Nutr 63 (Suppl 1): S75-S81, 2012.
18. Jin YH, Yim H, Park JH and Lee SK: Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis. Biochem Biophys Res Commun 305: 974-980, 2003.
19. Kaneko H and Nakanishi K: Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Clinical effects of medical ginseng korean red ginseng: Specifically its anti-stress action for prevention of disease. J Pharmacol Sci 95: 158-162, 2004.
20. Cheng Y, Shen LH and Zhang JT: Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 26: 143-149, 2005.
21. Su JH, Xu JH and Wang ZL: Improving enzymatic production of ginsenoside Rh2 from Rg3 by using nonionic surfactant. Appl Biochem Biotechnol 160: 1116-1123, 2010.
22. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS and Du W: Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 301: 185-192, 2011.
23. Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS and Ikejima T: Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol Sin 23: 315-322, 2002.
24. Park JS, Park EM, Kim DH, Jung K, Jung JS, Lee EJ, Hyun JW, Kang JL and Kim HS: Anti-infl ammatory mechanism of ginseng saponins in activated microglia. J Neuroimmunol 209: 40-49, 2009.
25. Choi IW, Kim DK, Ko HM and Lee HK: Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice Int Immunopharmacol 4: 1817-1828, 2004.
26. Bousquet J, Jeffery PK, Busse WW, Johnson M and Vignola AM: Asthma From bronchoconstriction to airways infl ammation and remodeling. Am J Respir Crit Care Med 161: 1720-1745, 2000.
27. Wegmann M: Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Rev Mol Diagn 9: 85-100, 2009.
28. Holt PG and Sly PD: Th2 cytokines in the asthma late-phase response. Lancet 370: 1396-1398, 2007.
29. Siebenlist U, Franzoso G and Brown K: Structure regulation and function of NF-kappa B. Ann Rev Cell Biol 10:405-455, 1994.
30. Baeuerle PA and Baltimore D: NF-kappa B: Ten years after. Cell 87:13-20, 1996.
31. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Ann Rev Immunol 14: 649-683, 1996.
32. Barnes PJ: Nuclear factor-kappa B. Int J Biochem Cell Biol 29: 867-870, 1997.
33. Ray A, Siegel MD, Prefontaine KE and Ray P: Anti-infl ammation: Direct physical association and functional antagonism between transcription factor NF-κB and the glucocorticoid receptor. Chest 107 (Suppl 3): S139, 1995.
34. Imanifooladi AA, Yazdani S and Nourani MR: The role of nuclear factor-kappaB in inflammatory lung disease. Inflamm Allergy Drug Targets 9: 197-205, 2010.
35. Schaeffer HJ and Weber MJ: Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999.
36. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000.
37. Han J and Ulevitch RJ: Emerging targets for anti-infl ammatory therapy. Nat Cell Biol 1: E39-E40, 1999.
38. Kumar A, Lnu S, Malya R, Barron D, Moore J, Corry DB and Boriek AM: Mechanical stretch activates nuclear factor-kappaB activator protein-1 and mitogen-activated protein kinases in lung parenchyma: Implications in asthma. FASEB J 17: 1800-1811, 2003.
39. Taube C, Nick JA, Siegmund B, Duez C, Takeda K, Rha YH, Park JW, Joetham A, Poch K, Dakhama A, et al: Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness. Am J Respir Cell Mol Biol 30: 837-843, 2004.
40. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW and Griswold DE: SB 239063 a potent p38 MAP kinase inhibitor reduces infl ammatory cytokine production airways eosinophil infiltration and persistence. J Pharmacol Exp Ther 293: 281-288, 2000.
41. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG and Wong WS: Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 171: 571-578, 2005.
42. Yi PF, Bi WY, Shen HQ, Wei Q, Zhang LY, Dong HB, Bai HL, Zhang C, Song Z, Qin QQ, et al: Inhibitory effects of sulfated 20(S)-ginsenoside Rh2 on the release of pro-inflammatory mediators in LPS-induced RAW 264-7 cells. Eur J Pharmacol 712: 60-66, 2013.